Search

Your search keyword '"Nagakane Y"' showing total 137 results

Search Constraints

Start Over You searched for: Author "Nagakane Y" Remove constraint Author: "Nagakane Y"
137 results on '"Nagakane Y"'

Search Results

2. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

4. Oral anticoagulants in the oldest old with recent stroke and atrial fibrillation

5. Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation

7. Diffusion tensor imaging may help the determination of time at onset in cerebral ischaemia

15. Rivaroxaban for stroke prevention after embolic stroke of undetermined source

16. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

17. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

21. Incidental Acute Infarcts Identified on Diffusion-Weighted Images: A University Hospital-Based Study

22. The effects of alteplase 3 to 6 hours after stroke in the epithet-defuse combined dataset: Post Hoc case-control study.

23. EPITHET: Positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration

24. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review

27. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: A systematic review

35. Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke.

37. [Five-year outcomes in patients with ischemic stroke or transient ischemic attack after widespread use of direct oral anticoagulants].

38. Magnetic resonance imaging features and stroke etiology of ischemic stroke in essential thrombocythemia.

39. Absence of the Susceptibility Vessel Sign with Cancer-Associated Hypercoagulability-Related Stroke.

40. Cerebral Small Vessel Disease Burden for Bleeding Risk during Antithrombotic Therapy: Bleeding with Antithrombotic Therapy 2 Study.

41. Effects of preceding antiplatelet agents on severity of ischemic stroke in patients with a history of stroke.

42. D-Dimer Trends Predict Recurrent Stroke in Patients with Cancer-Related Hypercoagulability.

43. Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes with Alteplase at 0.6 mg/kg in Clinical Practice: THAWS2 Study.

44. Long-term effectiveness of anticoagulants in oldest-old stroke survivors with atrial fibrillation.

45. Early Recurrence in Patients with Symptomatic, Non-Cardioembolic, Internal Carotid Artery Occlusion.

46. Cerebral microbleeds development after stroke thrombolysis: A secondary analysis of the THAWS randomized clinical trial.

47. [Brain infarction and cerebral venous thrombosis in paroxysmal nocturnal hemoglobinuria: case report].

48. Prediction of recurrent stroke among ischemic stroke patients with atrial fibrillation: Development and validation of a risk score model.

49. FLAIR vascular hyperintensity with DWI for regional collateral flow and tissue fate in recanalized acute middle cerebral artery occlusion.

50. Attack Interval Is the Key to the Likely Pathogenesis of Multiple Transient Ischemic Attacks.

Catalog

Books, media, physical & digital resources